HUMAW · Insider Trading

Humacyte, Inc. Warrant

Every open-market purchase and sale reported by HUMAW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
8
code P
Sales
4
code S
Reporting Insiders
10
current holders
HUMAW — Recent Form 4 Transactions (latest 2026-06-12)
FiledInsiderRole TypeSharesValue
2026-06-12 John Philip Bamforth Director A +80,000 deriv. —
2026-06-12 Brady W Dougan Director A — —
2026-06-12 Susan Richards Windham-Bannister Director A +80,000 deriv. —
2026-06-12 Diane Seimetz Director A +80,000 deriv. —
2026-06-12 Charles Bruce Green Director A +80,000 deriv. —
2026-06-12 Laura E Niklason President, CEO and Director A +80,000 deriv. —
2026-06-12 Max N. Wallace Director A +80,000 deriv. —
2026-06-12 Michael T. Constantino Director A +80,000 deriv. —
2026-06-12 Keith Anthony Jones Director A +80,000 deriv. —
2026-06-12 Kathleen Sebelius Director A +80,000 deriv. —
2026-06-12 Emery N. Brown Director A +80,000 deriv. —
2026-05-20 Michael T. Constantino Director Buy +11,000 +$9.84K
2026-05-20 Shamik J Parikh Chief Medical Officer Sell −45,887 −$41.15K
2026-05-20 Dale A. Sander CFO and Chief Corp. Dev. Off Sell −45,887 −$41.15K
2026-05-20 Kathleen Sebelius Director Buy +56,818 +$50.00K
2025-12-08 FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ — — — —
2025-11-17 Brady W Dougan Director A +311,100 deriv. —
2025-11-17 Laura E Niklason President, CEO and Director A +311,100 deriv. —
2025-11-17 Shamik J Parikh Chief Medical Officer A +311,100 —
2025-11-17 Dale A. Sander CFO and Chief Corp. Deve. Off. A +311,100 —
2025-08-20 Laura E Niklason President, CEO and Director Sell −2,241,045 −$3.73M
2025-08-20 Brady W Dougan Director Sell −2,241,045 −$3.73M
2025-06-16 Keith Anthony Jones Director A +80,000 deriv. —
2025-06-16 Todd Pope Director A +80,000 deriv. —
2025-06-16 Susan Richards Windham-Bannister Director A +80,000 deriv. —
2025-06-16 Emery N. Brown Director A +80,000 deriv. —
2025-06-16 Max N. Wallace Director A +80,000 deriv. —
2025-06-16 Diane Seimetz Director A +80,000 deriv. —
2025-06-16 Kathleen Sebelius Director A +80,000 deriv. —
2025-06-16 Charles Bruce Green Director A +80,000 deriv. —
2025-06-16 Michael T. Constantino Director A +80,000 deriv. —
2025-06-16 Brady W Dougan Director A — —
2025-06-16 John Philip Bamforth Director A +80,000 deriv. —
2025-06-16 Laura E Niklason President, CEO and Director A — —
2025-04-15 William John Scheessele Chief Commercial Officer Buy +6,493 +$10.00K
2025-04-14 Dale A. Sander CFO and Chief Corp. Deve. Off. Buy +20,000 +$30.60K
2025-04-14 Shamik J Parikh Chief Medical Officer Buy +7,500 +$11.62K
2025-04-08 Kathleen Sebelius Director Buy +50,000 +$66.00K
2025-04-08 Charles Bruce Green Director Buy +6,000 +$7.74K
2025-04-08 Michael T. Constantino Director Buy +16,000 +$20.16K
2025-01-23 Brady W Dougan Director A +1,130,311 deriv. —
2025-01-23 Heather Ledbetter Prichard Chief Operating Officer A +283,101 deriv. —
2025-01-23 Dale A. Sander CFO and Chief Corp. Deve. Off. A +283,101 deriv. —
2025-01-23 Shamik J Parikh Chief Medical Officer A +283,101 deriv. —
2025-01-23 Laura E Niklason President, CEO and Director A +1,130,311 deriv. —
2025-01-23 William John Scheessele Chief Commercial Officer A +283,101 deriv. —
2025-01-23 Yang Cao Chief Regulatory Officer A +283,101 deriv. —
2024-12-20 Heather Ledbetter Prichard Chief Operating Officer A +525 deriv. —
2024-12-20 Laura E Niklason President, CEO and Director A +525 deriv. —
2024-12-20 Dale A. Sander CFO and Chief Corp. Deve. Off. A +525 deriv. —
HUMAW — Current Insider Holders
InsiderRole Shares HeldValue
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/ — 18,312,735 $16.48K
Brady W Dougan Director 1,392,091 $1.25K
Laura E Niklason President, CEO and Director 1,392,091 $1.25K
Dale A. Sander CFO and Chief Corp. Dev. Off 307,813 $277
Shamik J Parikh Chief Medical Officer 272,713 $245
Kathleen Sebelius Director 148,025 $133
Max N. Wallace Director 64,555 $58
Michael T. Constantino Director 43,950 $40
William John Scheessele Chief Commercial Officer 22,018 $20
Charles Bruce Green Director 8,400 $8
HUMAW Insider Trading FAQ
Who are the insiders at HUMAW?
10 officers, directors and 10%+ beneficial owners currently report holdings in HUMAW via SEC Form 4.
Are HUMAW insiders buying or selling?
Across the 50 most recent Form 4 filings for HUMAW, 8 were open-market purchases (code P) and 4 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is HUMAW insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent HUMAW filing is dated 2026-06-12.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the HUMAW quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.